Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure

Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
Journal of pediatric endocrinology & metabolism: JPEM (Impact Factor: 1). 04/2011; 24(3-4):203-4. DOI: 10.1515/jpem.2011.123
Source: PubMed


Maternal adrenal cortical carcinoma in pregnancy is rare. We report a case of an infant born to a mother with a history of adrenal cortical carcinoma. The pregnancy was complicated by fetal exposure to mitotane and dexamethasone. Despite the potential teratogenic exposures, there was no evidence of adrenal dysfunction in the infant. Growth and development at 12 months of age are normal and prognosis appears favorable. The long-term impact of fetal exposure to mitotane and glucocorticoid requires further investigation.

7 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Context: Adrenocortical carcinoma (ACC) affects patients in a broad age group, including young women. Mitotane, an adrenolytic agent, is the mainstay of treatment after surgical removal of the tumor. There is extreme paucity of information regarding the effect of mitotane on childbearing potential and pregnancy outcome. Objective: The aim of the study was to describe and discuss the case of an ACC patient who conceived while on mitotane treatment. Current literature is reviewed. Patient and methods: A 33-year-old woman received mitotane treatment for 4 years due to metastatic ACC. Despite nearly therapeutic blood levels of the drug, the patient had regular menstruation and was able to conceive. Mitotane was stopped at gestation week 6. Although the drug continued to be detected in considerable amounts, the fetus developed normally, including morphologically intact adrenal glands. At gestation week 21, pregnancy was terminated due to ACC recurrence. Mitotane levels were undetectable in fetal cord blood and amniotic fluid. Conclusion: Our report suggests that mitotane, despite its action as an endocrine disruptor, does not affect normal gonadal function or an ability to conceive. The concern of placental transfer by this hydrophobic compound is not supported by our findings. However, we do not recommend drawing conclusions regarding the safety of mitotane in pregnancy, based on 1 or several case reports. Until more data are available, pregnancy should be avoided in women being treated with mitotane for ACC.
    The Journal of Clinical Endocrinology and Metabolism 12/2012; 98(2). DOI:10.1210/jc.2012-2839 · 6.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with often unfavorable prognosis. Here we summarize the knowledge about diagnosis, epidemiology, pathophysiology and therapy of ACC. Over the recent years multidisciplinary clinics have formed and the first international treatment trials have been conducted. This review focuses on evidence gained from recent basic science and clinical research and provides perspectives from the experience of a large multidisciplinary clinic dedicated to the care of patients with ACC.
    Endocrine reviews 01/2013; 35(2):er20131029. DOI:10.1210/er.2013-1029 · 21.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adrenal diseases, including Cushing syndrome (CS), primary aldosteronism (PA), pheochromocytoma, and adrenocortical carcinoma, are uncommon in pregnancy; a high degree of clinical suspicion must exist. Physiologic changes to the hypothalamus-pituitary-adrenal axis in a normal pregnancy result in increased cortisol, renin, and aldosterone levels, making the diagnosis of CS and PA in pregnancy challenging. However, catecholamines are not altered in pregnancy and allow a laboratory diagnosis of pheochromocytoma that is similar to that of the nonpregnant state. Although adrenal tumors in pregnancy result in significant maternal and fetal morbidity, and sometimes mortality, early diagnosis and appropriate treatment often improve outcomes. Copyright © 2015 Elsevier Inc. All rights reserved.
    Endocrinology and metabolism clinics of North America 06/2015; 44(2):381-397. DOI:10.1016/j.ecl.2015.02.006 · 3.40 Impact Factor